BioSpace News Archive

– LINZESS ® (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year – –Total revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million – – GAAP net income of $40 million and adjusted EBITDA of $46 million; ended Q1 2021 with $438 million in cash and cash equivalents –

- ZYNLONTA™ (loncastuximab tesirine-lpyl) granted accelerated FDA approval for patients with relapsed or refractory diffuse large B-cell lymphoma - Commercial launch progressing well; orders shipped - NCCN guidelines category 2A recommendation to reflect the broad FDA indication - Company to host conference call today at 8:30 a.m. EDT

Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins Revenue up 14% as sales momentum from Q4’20 continues Pre-clinical product revenue up 24% Operating margin significantly improves year-over-year on GAAP and adjusted basis

Dyno Therapeutics, Inc. , a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a $100 million Series A financing led by Andreessen Horowitz, with participation from a select syndicate of new investors

Recently Announced Phase 3 INVIGORATE Clinical Trial Results Indicated Statistically Significant Activity of Reproxalap in Ocular Itching and Redness Associated with Allergic Conjunctivitis Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Trials of Reproxalap in Dry Eye Disease Expected in the Second Half of 2021

SARS-CoV-2 Variant Booster Program Update : Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two Variants of Concern (B.1.351, P.1) in previously vaccinated clinical trial participants

XOMA Corporation (Nasdaq: XOMA) reported its first quarter 2021 financial results and provided a recent operations update.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, May 10, 2021 at 8:30 AM ET to discuss results for the first quarter 2021 and provide a business outlook for 2021. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that clinical investigators and senior leadership will present at five scientific and medical events in May 2021.

- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - Well-Resourced with Cash Runway Expected into the Second Half of 2024 -